1. Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
    Ranjan Pathak et al, 2020, Cancers CrossRef
  2. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
    Huayu Yang et al, 2019, Frontiers in Oncology CrossRef
  3. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT
    Lihong Fei et al, 2022, Frontiers in Genetics CrossRef
  4. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
    Stefanie N. Linch et al, 2015, Frontiers in Oncology CrossRef
  5. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment
    Jingfang Lv et al, 2023, Frontiers in Immunology CrossRef
  6. The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
    Jingchang Zhang et al, 2022, Frontiers in Oncology CrossRef
  7. Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity
    Aayushi Singh et al, 2023, Receptor Endocytosis and Signalling in Health and Disease - Part A CrossRef
  8. Prognostic value of PDL1 expression in pancreatic cancer
    David J. Birnbaum et al, 2016, Oncotarget CrossRef
  9. PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Mengyu Feng et al, 2017, Cancer Letters CrossRef

  10. The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells


    Ziwei Li et al, 2020, OncoTargets and Therapy CrossRef